New STORM-PE data show improved functional outcomes with CAVT plus anticoagulation

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE). The company reported that patients treated with the Penumbra CAVT system plus anticoagulation achieve…

New STORM-PE data show improved functional outcomes with CAVT plus anticoagulation

Robert Lookstein presents at SIR 2026 The 90-day results of the STORM-PE randomised controlled trial (RCT) have demonstrated that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving New York Heart Association (NYHA) cla…